AVXL · NASDAQ
Anavex Life Sciences (AVXL) Stock Price & Fundamentals
Anavex Life Sciences (AVXL) closed at $396.22 on Oct 9, 2026, up 0.98% from the previous close of $392.36.
Share price, past year
1Y +33.94%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $396.22 |
| Sep 30, 2026 | $397.88 |
| Aug 31, 2026 | $399.83 |
| Jul 31, 2026 | $354.66 |
| Jun 30, 2026 | $365.75 |
| May 29, 2026 | $359.20 |
| Apr 30, 2026 | $327.88 |
| Mar 31, 2026 | $329.45 |
| Feb 27, 2026 | $315.07 |
| Jan 30, 2026 | $320.94 |
| Dec 31, 2025 | $310.08 |
| Nov 28, 2025 | $312.16 |
| Oct 31, 2025 | $301.95 |
Key statistics
- Market cap
- $36.73B
- EPS (TTM)
- −$0.15
- Net income (TTM)
- −$13.02M
- Shares outstanding
- 92.7M
- 52-week range
- $288.60 – $408.76
Anavex Life Sciences's market cap is $36.73B, based on a share price of $396.22 and 92.7M shares outstanding as of Jun 30, 2026.
Financials
Anavex Life Sciences's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Anavex Life Sciences reported a net loss of $46.38M in fiscal 2025.
Company profile
- Name
- Anavex Life Sciences Corp.
- Ticker
- AVXL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 630 5th Avenue, 20th Floor, New York, NY 10111
- Fiscal year ends
- September
- SEC CIK
- 0001314052
Recent SEC filings
- Sep 28, 2026
- Sep 9, 2026
- Sep 2, 2026
- Aug 28, 2026
- Aug 28, 2026
- Aug 28, 2026
- Aug 28, 2026
- Aug 25, 2026
Frequently asked questions
What is Anavex Life Sciences's stock price?
Anavex Life Sciences (AVXL) closed at $396.22 on Oct 9, 2026, up 0.98% from the previous close of $392.36.
What is Anavex Life Sciences's market cap?
Anavex Life Sciences's market cap is $36.73B, based on a share price of $396.22 and 92.7M shares outstanding as of Jun 30, 2026.
Does Anavex Life Sciences pay a dividend?
Anavex Life Sciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Anavex Life Sciences Corp.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures